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Abstract
The ganglionic cell type in which varicella-zoster virus (VZV) is latent in humans was analyzed by
using antibodies raised against in vitro -expressed VZV open reading frame 63 protein. VZV open
reading frame 63 protein was detected exclusively in the cytoplasm of neurons of latently infected
human trigeminal and thoracic ganglia. This is, to our knowledge, the first identification of a
herpesvirus protein expressed during latency in the human nervous system.
Varicella-zoster virus (VZV) is an exclusively human herpesvirus that causes childhood chickenpox
(varicella), becomes latent in dorsal root ganglia, and frequently reactivates decades later to produce
shingles (zoster), mostly in the elderly. Unlike latent herpes simplex virus (HSV), VZV cannot be
rescued by explantation or cocultivation of ganglionic cells with indicator cells in vitro. Nevertheless,
postmortem analysis of latently infected sensory ganglia at all levels of the neuraxis revealed low levels
of virus DNA (1) from multiple regions of the VZV genome in most humans (2, 3), including
transcripts from no less than three regions of the VZV genome (4-6). Analysis of latently infected
ganglia by in situ hybridization has identified VZV nucleic acid in neurons (7, 8), including ganglionic
neurons in an animal model of VZV latency (9, 10), and in satellite cells (4, 11). The latter finding was
surprising, since VZV DNA is not integrated into cell DNA (12). Thus, the biology of VZV latency
and reactivation is best explained by virus residing in and reactivating from nondividing neurons. Since
antibodies against in vitro expressed product of VZV open reading frame (ORF) 63 were successfully
used to detect viral antigen in rat ganglia (13), we used the same antibodies to analyze the ganglionic
cell type in which VZV is latent in humans.
Methods
Tissue Samples
One trigeminal and multiple thoracic ganglia from nine adults and three infants were obtained within
24 hr after death. None of the subjects was immunocompromised before death, and at autopsy there
were no cutaneous signs of recent herpesvirus infection. The tissue samples were para-formaldehyde-
fixed and paraffin-embedded. Sections (5 μm) were deparaffinized with 100% xylene for 5 min
followed by 100% ethanol for 5 min. The xylene-alcohol treatment was repeated twice.
Immunohistochemistry
Unless indicated otherwise, all incubations were at room temperature. The deparaffinized sections were
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incubated with a 10% (vol/vol) solution of normal sheep serum for 1 hr followed by a 1:100 dilution of
either rabbit antiserum directed against the VZV ORF 63 protein (13) or normal rabbit serum (NRS) in
phosphate-buffered saline (PBS) for 30 min. Both rabbit sera had been preabsorbed with normal human
liver powder for 30 min and again for 20 hr at 4°C. Sections were rinsed with PBS, incubated for 20
min with a 1:300 dilution of biotinylated goat anti-rabbit IgG (DAKO) in PBS containing 5% NSS,
washed three times with PBS, incubated for 20 min with a 1:100 dilution of alkaline phosphatase-
conjugated streptavidin (DAKO), and washed three times with PBS. The color reaction was developed
for 5-30 min with fresh fuchsin substrate system (model K0698; DAKO). Levamisole was added to the
color reaction at a final concentration of 24 μg/ml. Sections were counterstained with Gill's
hematoxylin for 4 min, rinsed in water and mounted by using an aqueous medium. Except for the
deparaffinization step, VZV-infected and uninfected BSC-1 cells grown on coverslips and fixed in
acetone were treated identically.
Results and discussion
To analyze VZV expression in latently infected ganglia, one trigeminal and multiple thoracic ganglia
from nine adults and three infants were obtained within 24 hr after death. Enzyme immunoassay (14)
revealed antibody to VZV in the serum of all of the adults. Serum available from only one of the three
infants did not contain antibody to VZV. Liquid PCR amplification with VZV-specific primers (3)
revealed VZV DNA in all adult ganglia but not in any infant ganglia in DNA extracted from a small
portion of each ganglion (data not shown). The remaining portions of each ganglion were analyzed
immuno-histochemically by using antibodies raised in rabbit against the 30.5-kDa-VZV ORF 63
protein, expressed as a glutathione S-transferase fusion protein in Escherichia coli and purified as
described (13). VZV-infected and uninfected BSC-1 (African green monkey kidney) cells served as
positive and negative controls, respectively.
In VZV-infected BSC-1 cells, two focal areas of typical VZV cytopathology containing VZV ORF 63
protein were seen (Fig. \A). No signal was detected in uninfected cells (Fig. 1B) or in HSV-infected
BSC-1 cells (not shown) or when NRS was applied to VZV-infected BSC-1 cells (not shown). In
ganglia acquired 17 hr after death from a 46-year-old man who died of atherosclerosis, a characteristic
red color revealed VZV ORF 63 protein exclusively in the cytoplasm of three neurons (Fig. 1C). No
signal was detected when NRS was applied to an adjacent section of the same ganglion (Fig. 1D). A
nonspecific brown color in neurons (Fig. 1 C and D) represents pigmentary changes often seen in
hematoxylin-stained human ganglia. Intense red staining was detected in the cytoplasm of a neuron in
adjacent sections of a different dorsal root ganglion of the same subject (Fig. 1E and F).
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FIG. 1. Detection of VZV ORF 63 protein in human thoracic ganglia latently infected with VZV. (A and
B) VZV-infected (A) and uninfected BSC-1 cells (B) incubated with antiserum raised against VZV ORF
63 protein (anti-63). (x 77.) (C and D) Section of a thoracic ganglion obtained from a VZV-
seropositive 46-year-old man and incubated with anti-63 (C) or NRS (D): arrows point to three
neurons positive for VZV ORF 63 protein. (x122.) (E and F) Adjacent sections of a different thoracic
ganglion from the same subject and incubated with anti-63: arrows point to neurons positive for VZV
ORF 63 protein. (x122.) (G) Thoracic ganglion derived from a VZV-seronegative 2-month-old infant
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and incubated with anti-63. (x122.)
A lighter red color was also often seen in multiple neurons of latently infected ganglia, suggesting a
more diffuse, perhaps lower abundance infection. The
red VZV ORF 63 protein-specific staining was never seen in satellite (capsular) cells, capillaries,
connective tissue, nerve fascicles within the ganglia, or nerve rootlets entering the
ganglia. No signal was detected when the antiserum against VZV ORF 63 protein was applied to
ganglia of a 2-month-old infant who died of sepsis complicating a congenital omphalocele and
pulmonary hypoplasia (Fig. 1G).
Overall, VZV ORF 63 protein was found in five ganglia (four thoracic and one trigeminal) from two
adults. In one of these adults, VZV ORF 63 protein was detected in all 10 sections from four of five
thoracic ganglia, but not in any of 10 sections from the fifth thoracic ganglion. In the second adult,
VZV ORF 63 protein was detected in all four sections from the trigeminal ganglion. In positive
sections, VZV ORF 63 protein was detected in the cytoplasm of two to four neurons. VZV ORF 63
protein was not detected in any of four sections prepared from each of 16 ganglia from seven other
adults, or in any of four sections from each of nine ganglia from three infants. The detection of VZV
DNA in nearly all ganglia but VZV ORF 63 protein only in some latently infected ganglia might reflect
sampling—i.e., analysis of every section of each ganglion containing VZV DNA for VZV ORF 63
protein might have revealed additional positive ganglia. Alternatively, virus expression might differ in
different ganglia; for example, in ganglia latently infected with HSV, the number of neurons containing
HSV DNA is far greater than those revealing latency-associated transcripts (15). Finally, in the subjects
whose ganglia contained VZV ORF 63 protein, virus reactivation might have occurred, although this
seems unlikely since there was no clinical evidence of zosteriform rash before death; no history of
prolonged neuralgic pain, which may precede rash (preherpetic neuralgia) (16); no history of der-
matomal distribution pain without rash (zoster sine herpete) (17); and no history of postherpetic
neuralgia suggesting a low-grade ganglionitis (18). Furthermore, histologic examination of ganglia
revealed no neuronophagia, inclusion bodies, or an inflammatory response.
The VZV ORF 63 protein is an immediate-early (IE) gene-encoded protein in virus-infected cells in
culture (13). Furthermore, VZV ORF 63 protein has been detected in latently infected rat neurons (13),
and we have identified the protein exclusively in the cytoplasm of neurons in latently infected human
ganglia. Although VZV does not spontaneously reactivate from rat ganglia, analysis of the physical
state of VZV nucleic acid in rat ganglia months after experimental infection might provide useful
information about human VZV latency. A comparison of the virus burden during latency in ganglionic
neurons of humans and rats cannot yet be made, since our ganglia were obtained from elderly humans,
whereas Debrus et al. (13) studied ganglia from middle-aged rats months after experimental infection.
The HSV homologue of VZV ORF 63 is HSV-1 IE 68 (19). The HSV-1 IE 68 gene is not transcribed
in ganglia latently infected with HSV. In fact, during HSV latency in humans, the only region of the
viral genome transcribed is a 2.0-kb fragment of DNA within the repeat regions that synthesizes two
RNAs, 2.0 and 1.5 kb in size (20). In this regard, HSV and VZV latency are different.
Finally, the translation products of the three VZV RNAs that have been identified during latency in
humans (VZV genes 27, 29, and 62) have not been studied, since antibodies directed against these
ORFs have not yet been produced. Those virus antigens may be present at a level different from that of
VZV ORF 63 protein, or possibly not expressed at all. This is, to our knowledge, the first report of the
identification of a herpesvirus protein expressed during latency in the human nervous system.
Knowledge of other VZV genes expressed at the peptide level during latency should provoke
hypotheses regarding the mechanism(s) of latency.
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